Each day matters when it comes to slowing the progression of Alzheimer’s disease (AD), so it is imperative that health care professionals in this field are able to provide optimal care for patients with AD in a timely manner while applying the latest clinical trial data to practice, including the varied safety and efficacy data on new and emerging amyloid-targeting therapies (ATTs). ATTs have been shown to be promising in delaying disease progression in individuals with mild cognitive impairment or early dementia due to AD. To realize the full potential of ATTs, HCPs need education on clinical data of ATT agents in order to appropriately translate that information to improve diagnosis and management of AD.
In this CME Outfitters Snack, expert faculty will review data presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and will focus on established, new, and emerging ATTs as well as a case-based discussion on clinical impacts and applications to provide point-of-care tactics that will have a positive impact on patient outcomes.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/what-do-the-data-on-new-and-emerging-atts-mean-to-clinical-practice/
- Start Date: 2023-12-20 06:00:00
- End Date: 2023-12-20 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Lilly (Any division) - Amount: 84250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine